Last updated on February 2018

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: follicular lymphoma | Follicular Lymphoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Histologically confirmed FL.
    Documented CD20+ FL.
    Relapsed or refractory to any prior rituximab-containing regimen.
    Previously treated with a maximum of 4 cancer-directed treatment regimens.
    At least 1 measurable lesion > 1.5 cm in at least 1 dimension by computed tomography
    or magnetic resonance imaging.
    Must be willing to undergo an incisional or excisional lymph node biopsy of accessible
    adenopathy or provide the most recent, available archived tumor biopsy.
    Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

You may not be eligible for this study if the following are true:

  • Clinical evidence of transformation to a more aggressive subtype of lymphoma or Grade
    3B FL.
    History of central nervous system lymphoma (either primary or metastatic).
    Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host
    disease following allogeneic transplant or autologous stem cell transplant within the
    last 3 months before the date of the first dose of study drug administration.
    Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5
    half-lives (whichever is longer) before the first dose of study drug.
    Prior treatment with a selective PI3Kδ inhibitor or a pan PI3K inhibitor.
    Prior treatment with bendamustine (within 12 months of the start of study treatment).
    Subjects with prior bendamustine treatment (> 12 months before the start of study
    treatment) are eligible if they meet the following criteria:
    Did not discontinue because of tolerability concerns.
    Achieved either partial or CR to the bendamustine regimen of at least 12 months
    in duration before relapse/progression.
    Experienced progression following a regimen containing an alkylating agent.
    Received prior obinutuzumab.
    Received rituximab within 4 weeks of study start.
    Prior treatment-related toxicities that have not resolved to ≤ Grade 1 before the date
    of study drug administration except for stable chronic toxicities (≤ Grade 2) not
    expected to resolve (eg, stable Grade 2 peripheral neurotoxicity).
    Received any prior monoclonal antibody (except an anti-CD20 antibody) within 90 days
    before the date of study start.
    History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
    (eg, subjects in whom re-administration with rituximab would be contraindicated for
    afety reasons).

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.